This week, news from the psychedelic sector has been dominated by patent applications and earnings being released. Here’s the run down of this week’s news. Cybin (CYBN.NE) It’s been…
psychedelic therapy
For the vast majority of the history of human use of psychedelics, they have been seen as something sacred, a gift from God or mother nature herself. Ayahuasca, which…
Mind Cure (MCUR.C), a leader in advanced proprietary technology for psychedelic therapy, has provided updates regarding its financial position, near-term revenue strategy, and a timeline for iSTRYM’s market launch….
Cybin (CYBN.NE) announced that they have successfully demonstrated Proof of Concept for their deuterated tryptamine programs, CYB003 and CYB004. The Proof of Concept revolves around the duration of psilocybin….
Cybin (CYBN.NE) is in a prime position as the push for psychedelic medicine surges across North America and around the world. Scientific evidence supports the life-changing impact of medicinal…
Cybin (CYBN.NE) announced they had completed their 20th pre-clinical study and are progressing their CYB003 and CYB004 proprietary psychedelic molecules into studies that will enable them to be tested…
Red Light Holland (TRIP.C) launched their virtual telecounseling membership program today. The membership program is available on the company’s iMicrodose digital care app available in the Netherlands. Virtual support…
Mind Cure Health Inc. has completed its initial strategic equity investment. The investment equates to approximately 13-per-cent ownership in ATMA Journey Centers Inc. in accordance with the terms specified…
Mind Medicine (MMED.E) closed a bought deal short-form prospectus offering, issuing 27,381,500 units for $1.05 and brought in $28,750,575 today, according to a press release. After the financing, the…
It’s a safe bet to say that virtual reality hasn’t fulfilled its promise. The prospect of a virtual environment for recreational purposes was a hot ticket back when it…